JP2024507938A - 骨髄線維症の治療としてのｂｅｔ阻害剤の使用 - Google Patents

骨髄線維症の治療としてのｂｅｔ阻害剤の使用 Download PDF

Info

Publication number
JP2024507938A
JP2024507938A JP2023551767A JP2023551767A JP2024507938A JP 2024507938 A JP2024507938 A JP 2024507938A JP 2023551767 A JP2023551767 A JP 2023551767A JP 2023551767 A JP2023551767 A JP 2023551767A JP 2024507938 A JP2024507938 A JP 2024507938A
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound
formula
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023551767A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024507938A5 (https=
Inventor
アロンチック，イーダ
バレンシア，ロクサーナ バレリア ベルトラン
ソラジャ カランシオ アントン，マリア
エイチ チャン，ヘンリー
コーカー，ショデインデ
ダス，シャルミラ
ホープ フィルバロフ，エレン
マルフエンダ，カルラ グアリノス
ハンナ，ビショイ
リウ，ユー
ニコロバ，ザリアナ
エスポージト，オリアーナ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Impact Biomedicines Inc
Original Assignee
Impact Biomedicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Impact Biomedicines Inc filed Critical Impact Biomedicines Inc
Publication of JP2024507938A publication Critical patent/JP2024507938A/ja
Publication of JP2024507938A5 publication Critical patent/JP2024507938A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Disintegrating Or Milling (AREA)
JP2023551767A 2021-02-25 2022-02-24 骨髄線維症の治療としてのｂｅｔ阻害剤の使用 Pending JP2024507938A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP21382163.0 2021-02-25
EP21382163 2021-02-25
US202163232866P 2021-08-13 2021-08-13
US63/232,866 2021-08-13
US202263297098P 2022-01-06 2022-01-06
US63/297,098 2022-01-06
PCT/US2022/017678 WO2022182857A1 (en) 2021-02-25 2022-02-24 Use of a bet inhibitor alone or in combination with fedratinib or ruxolitinib for treating a hematological malignancy such as myelofibrosis

Publications (2)

Publication Number Publication Date
JP2024507938A true JP2024507938A (ja) 2024-02-21
JP2024507938A5 JP2024507938A5 (https=) 2025-03-04

Family

ID=80786345

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023551767A Pending JP2024507938A (ja) 2021-02-25 2022-02-24 骨髄線維症の治療としてのｂｅｔ阻害剤の使用

Country Status (12)

Country Link
US (2) US12357621B2 (https=)
EP (1) EP4297750A1 (https=)
JP (1) JP2024507938A (https=)
KR (1) KR20230148208A (https=)
AU (1) AU2022227673A1 (https=)
CA (1) CA3206708A1 (https=)
CL (1) CL2023002497A1 (https=)
IL (1) IL304697A (https=)
MX (1) MX2023009858A (https=)
TW (1) TW202302095A (https=)
WO (1) WO2022182857A1 (https=)
ZA (1) ZA202307538B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022261204A1 (en) 2021-06-08 2022-12-15 The Regents Of The University Of California Anticancer compounds
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015100282A1 (en) * 2013-12-24 2015-07-02 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
JP2018530554A (ja) * 2015-10-02 2018-10-18 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ブロモドメイン阻害薬及びチェックポイント阻害薬による併用療法
WO2020051572A1 (en) * 2018-09-07 2020-03-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Brd4-jak2 inhibitors
WO2020146440A1 (en) * 2019-01-09 2020-07-16 Celgene Corporation Antiproliferative compounds and second active agents for use in treating multiple myeloma
WO2021247064A1 (en) * 2020-06-03 2021-12-09 Incyte Corporation Combination of ruxolitinib with incb057643 for treatment of myeloproliferative neoplasms

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5191391B2 (ja) 2005-11-01 2013-05-08 ターゲジェン インコーポレーティッド キナーゼのビ−アリールメタ−ピリミジン阻害剤
SG10202003901UA (en) 2005-12-13 2020-05-28 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
KR20150036210A (ko) 2007-06-13 2015-04-07 인사이트 코포레이션 야누스 키나제 억제제（Ｒ）―３―（４―（７Ｈ―피롤로［２，３－ｄ］피리미딘―4―일）―1Ｈ―피라졸―1―일）―３―사이클로펜틸프로판니트릴의 염
AU2010363329A1 (en) 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
US9458156B2 (en) 2014-12-23 2016-10-04 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
BR112021005518A2 (pt) 2018-09-25 2021-06-29 Impact Biomedicines, Inc. métodos para tratar distúrbios mieloproliferativos
US12559463B2 (en) 2019-02-12 2026-02-24 Impact Biomedicines Inc. Crystalline forms of a JAK2 inhibitor

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015100282A1 (en) * 2013-12-24 2015-07-02 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
JP2018530554A (ja) * 2015-10-02 2018-10-18 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ブロモドメイン阻害薬及びチェックポイント阻害薬による併用療法
WO2020051572A1 (en) * 2018-09-07 2020-03-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Brd4-jak2 inhibitors
WO2020146440A1 (en) * 2019-01-09 2020-07-16 Celgene Corporation Antiproliferative compounds and second active agents for use in treating multiple myeloma
WO2021247064A1 (en) * 2020-06-03 2021-12-09 Incyte Corporation Combination of ruxolitinib with incb057643 for treatment of myeloproliferative neoplasms

Also Published As

Publication number Publication date
IL304697A (en) 2023-09-01
US12357621B2 (en) 2025-07-15
CA3206708A1 (en) 2022-09-01
WO2022182857A1 (en) 2022-09-01
TW202302095A (zh) 2023-01-16
AU2022227673A9 (en) 2024-09-19
EP4297750A1 (en) 2024-01-03
ZA202307538B (en) 2026-01-28
US20220265617A1 (en) 2022-08-25
US20250367174A1 (en) 2025-12-04
AU2022227673A1 (en) 2023-08-17
CL2023002497A1 (es) 2024-01-12
MX2023009858A (es) 2023-09-12
KR20230148208A (ko) 2023-10-24

Similar Documents

Publication Publication Date Title
JP2024507938A (ja) 骨髄線維症の治療としてのｂｅｔ阻害剤の使用
JP2024012493A (ja) 消化管間質腫瘍の治療のための併用療法
JP6090836B2 (ja) 化学療法剤の抗腫瘍活性増強剤
CA2525366A1 (en) Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
EP2786750B2 (en) Agent for reducing adverse side effects of kinase inhibitor
CN108430475B (zh) 用于治疗慢性咳嗽的奥维匹坦
US20090312290A1 (en) Combination of a nitrogen mustard analogue and imatinib for treatment of chronic lymphocytic leukemia
BR112020022148A2 (pt) Métodos de tratamento de câncer
CN115006397A (zh) 一种预防或治疗肿瘤疾病的药物用途
CA3096156A1 (en) Use of inhibitors of bcr-abl mutants for the treatment of cancer
US10576050B2 (en) Methods and compositions for treatment of cancer
US20090048173A1 (en) Use Of Dipyridamole For Treatment Of Resistance To Platelet Inhibitors
KR20210084442A (ko) 포도막 흑색종 치료를 위한 병용 요법
TWI849001B (zh) Mcl-1抑制劑及米哚妥林(midostaurin)之組合，其用途及醫藥組合物
EA050366B1 (ru) Применение ингибиторов bet отдельно или в комбинации с федратинибом или с руксолитинибом для лечения гематологического злокачественного новообразования, такого как миелофиброз
WO2023011488A1 (zh) 一种药物组合及其用途
CN117615759A (zh) Bet抑制剂单独或者与菲卓替尼或芦可替尼组合用于治疗血液恶性肿瘤如骨髓纤维化的用途
RU2415672C2 (ru) Производные пиримидиламинобензамида для лечения синдрома гиперэозинофилии
CN101267837B (zh) 用于治疗系统性肥大细胞增生症的组合物
MX2008001971A (es) Combinacion de compuestos organicos.
WO2025078276A1 (en) Combination of a parp-1 selective inhibitor and temozolimde and its use in the treatment of glioma
WO2025056055A1 (zh) 新一代egfr抑制剂单药或联合使用在制备肿瘤疾病的药物中的应用
TW202515550A (zh) 三并環類抑制劑與抗癌劑在製備抗腫瘤藥物中的聯合應用
AU2024304092A1 (en) Use of akt inhibitor in preparation of drug for preventing or treating breast cancer
CN121041280A (zh) 亚氨基砜类化合物治疗淋巴瘤的用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250221

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260324